Insider Selling: Tempus AI (NASDAQ:TEM) EVP Sells $1,098,762.28 in Stock

Tempus AI, Inc. (NASDAQ:TEM) EVP Andrew Polovin sold 22,148 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total transaction of $1,098,762.28. Following the sale, the executive vice president directly owned 146,067 shares of the company’s stock, valued at $7,246,383.87. This represents a 13.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Andrew Polovin also recently made the following trade(s):

• On Wednesday, August 19th, Andrew Polovin sold 7,927 shares of Tempus AI stock. The stock was sold at an average price of $56.00, for a total transaction of $443,912.00.

Tempus AI Trading Up 8.8%

Shares of NASDAQ TEM traded up $5.40 during midday trading on Thursday, reaching $66.65. The stock had a trading volume of 20,103,049 shares, compared to its average volume of 5,600,288. The firm has a market cap of $12.03 billion, a price-to-earnings ratio of -46.28 and a beta of 3.58. Tempus AI, Inc. has a twelve month low of $40.77 and a twelve month high of $104.32. The company has a debt-to-equity ratio of 3.06, a quick ratio of 3.16 and a current ratio of 3.30. The company’s 50 day moving average price is $52.44 and its 200 day moving average price is $51.21.

Tempus AI (NASDAQ:TEM) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The company had revenue of $382.49 million for the quarter, compared to analyst estimates of $379.69 million. During the same period in the prior year, the firm posted ($0.22) EPS. The company’s quarterly revenue was up 21.6% on a year-over-year basis. As a group, sell-side analysts expect that Tempus AI, Inc. will post -1.38 EPS for the current year.

Hedge Funds Weigh In On Tempus AI

Several institutional investors have recently made changes to their positions in TEM. JPL Wealth Management LLC bought a new position in shares of Tempus AI during the 3rd quarter worth about $26,000. Los Angeles Capital Management LLC acquired a new stake in shares of Tempus AI in the 4th quarter valued at about $27,000. Harvest Fund Management Co. Ltd bought a new stake in Tempus AI in the 3rd quarter valued at about $38,000. Whittier Trust Co. increased its position in Tempus AI by 190.0% in the 1st quarter. Whittier Trust Co. now owns 870 shares of the company’s stock valued at $41,000 after buying an additional 570 shares in the last quarter. Finally, EverSource Wealth Advisors LLC raised its stake in Tempus AI by 88.8% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 691 shares of the company’s stock worth $44,000 after buying an additional 325 shares during the period. Institutional investors and hedge funds own 24.22% of the company’s stock.

More Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: BTIG raised its price target to $80 from $70 and maintained a “Buy” rating, implying roughly 20% upside from the referenced price. The upgrade provided a direct catalyst for investor buying. BTIG raises Tempus AI price target
• Positive Sentiment: Investor attention is focusing on Tempus AI’s approximately $1.5 billion stock-based agreement to acquire Personalis. The deal is increasingly viewed as strategically valuable because Personalis’ genomic data and cancer-testing capabilities could strengthen Tempus’ precision-medicine and drug-development platform. Tempus AI biotech deal attracts investor attention
• Positive Sentiment: Moderna’s reported cancer-vaccine progress, alongside developments involving Merck, has encouraged investors to believe Tempus’ Personalis acquisition could benefit from increased demand for genomic data and personalized cancer treatment. The connection is indirect, but it has improved sentiment around Tempus’ strategic positioning. Tempus AI stock rises after Merck-Moderna cancer vaccine breakthrough
• Positive Sentiment: The rally was accompanied by unusually high options activity, with investors buying 40,671 call contracts—about 57% above average daily call volume—signaling increased bullish speculation and potentially reinforcing upward momentum.
• Neutral Sentiment: Technical factors also contributed: TEM moved above key moving averages, while coverage characterized the move as a possible short squeeze. These conditions can accelerate gains but may also increase volatility. Tempus AI stock technical rally

Analysts Set New Price Targets

A number of brokerages have weighed in on TEM. Freedom Capital upgraded Tempus AI to a “hold” rating in a report on Tuesday, June 30th. BTIG Research boosted their price objective on Tempus AI from $70.00 to $80.00 and gave the company a “buy” rating in a research note on Thursday. Piper Sandler cut their target price on Tempus AI from $58.00 to $56.00 and set a “neutral” rating on the stock in a research report on Tuesday, August 4th. Needham & Company LLC reissued a “buy” rating and issued a $75.00 price target on shares of Tempus AI in a research note on Friday, July 31st. Finally, Guggenheim increased their price target on Tempus AI from $60.00 to $65.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. Nine research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $65.69.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.